Last updated on April 17, 2014 at 8:41 EDT

EFIC-Grünenthal Grant Supports Young Scientists

April 23, 2012

AACHEN, Germany, April 23, 2012 /PRNewswire/ –

Apply for 2012 at http://www.e-g-g.info

Young scientists from across Europe are invited to apply for the EFIC-Gruenenthal
Grant (E-G-G) 2012, one of the most highly regarded pain research grants worldwide.
Provided by the European Federation of IASP(R) Chapters (EFIC(R)) and the pharmaceutical
company and pain expert Gruenenthal GmbH, this grant supports young scientists early in
their career in conducting innovative and exploratory clinical pain research projects.

Gruenenthal donates a total of EUR 200,000 for the biennial grant, which is shared
between the awarded scientists and is intended to support them early in their career. The
individual grants are valued at up to EUR 40,000 per project for a duration of up to two
years. The decision of the awards is made independently by the EFIC(R) Committee on

Interested young scientists can submit their research projects online at:
http://www.e-g-g.info until the end of 2012.

About EFIC(R)

The European Federation of IASP(R) Chapters (EFIC(R)) is a multidisciplinary
professional organisation in the field of pain research and medicine, consisting of the 35
so-called chapters of the International Association of the Study of Pain (IASP(R)), which
are the IASP(R) approved official pain societies in each country. Established in 1993,
EFIC’s constituent chapters represent pain societies from 35 European countries and close
to 20,000 scientists, physicians, nurses, physiotherapists, psychologists and other
healthcare professionals across Europe, who are involved in pain management and pain

About Gruenenthal

The Gruenenthal Group is an independent, family-owned international research based
pharmaceutical company headquartered in Aachen, Germany. Building on its unique position
in pain, its objective is to become the most patient-centric company to be a leader in
therapy innovation. Gruenenthal is one of the last five research-oriented pharmaceutical
corporations with headquarters based in Germany which sustainably invests in research and
development. These investments amounted to about 25 % of revenues in 2011. Gruenenthal’s
research and development strategy concentrates on select fields of therapy and
state-of-the-art technologies. We focus on the intensive search for new ways to treat pain
better, more effectively and with fewer side-effects than before. Altogether, the
Gruenenthal Group has affiliates in 26 countries worldwide. Gruenenthal products are sold
in more than 155 countries and approx. 4,500 employees are working for the Gruenenthal
Group worldwide. In 2011, Gruenenthal reached estimated revenues of 947 Mio EUR. More
information: http://www.grunenthal.com.

Contact: Frank Schonrock, Vice President Corporate Communications
Phone: +49-241-569-2161, Fax: +49-241-569-3539, frank.schoenrock@grunenthal.com

Gruenenthal GmbH, 52099 Aachen, Germany, (http://www.grunenthal.com)

SOURCE Grunenthal GmbH

Source: PR Newswire